Endocrine
Secretagogues & GHS
Standardizing the investigation of natural somatic axis modulation. High-purity CJC-1295, Ipamorelin, and GHRH analogs for precise hormonal signaling research.
99.4%
HPLC Purity Floor
Selectivity
Zero Prolactin Interference
Pulsatile
GH Signaling Models
Verified
Somatic Axis Targets
Quantifying the Somatotropic
Signaling Axis
Growth hormone (GH) secretion is a complex physiological process regulated by a delicate balance of stimulating and inhibiting factors. In the context of research endocrinology, secretagogues are synthetic ligands that trigger the endogenous release of GH from the pituitary gland. Unlike exogenous GH administration, which can lead to negative feedback inhibition, secretagogues work within the body’s natural feedback loops—mimicking the pulsatile release patterns that characterize a healthy somatic axis.
Research into compounds like CJC-1295 and Ipamorelin has provided labs with the tools to investigate physiological optimization, muscle protein synthesis, and metabolic vitality without the risk of pituitary desensitization common in older generations of ligands. At Vitanx Research, we provide the high-fidelity chemical inputs required to ensure these hormonal assays yield reproducible, baseline-verified data.
CJC-1295: The GHRH Receptor Analog
CJC-1295 is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH). It is a modified 29-amino acid peptide that mimics the first 29 amino acids of GHRH, often referred to as Sermorelin. The primary research benefit of CJC-1295 over Sermorelin is its significantly extended half-life, achieved through amino acid substitutions that prevent rapid enzymatic degradation as documented in the Journal of Clinical Endocrinology & Metabolism.
DAC vs. Non-DAC: A Researcher’s Choice
In analytical research, CJC-1295 is often discussed in two forms: with or without the Drug Affinity Complex (DAC). DAC allows the peptide to bind to serum albumin, extending its activity for several days. However, for labs investigating acute pulsatile response, “CJC-1295 No DAC” (also known as Mod GRF 1-29) is preferred as it more closely mimics the natural GHRH release during sleep cycles.
Signaling via cAMP Pathway
Once bound to the GHRH receptor on pituitary somatotrophs, CJC-1295 stimulates adenylyl cyclase, which increases intracellular levels of cyclic AMP (cAMP). This initiates a phosphorylation cascade that ultimately leads to the release of stored Growth Hormone and the transcription of new GH mRNA, a process researchers trace via NCBI-monitored physiological markers.
Ipamorelin: The Elite Growth Hormone Secretagogue
Ipamorelin is a selective pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a potent mimetic of ghrelin, the endogenous ligand for the GHS-R1a receptor. What distinguishes Ipamorelin in laboratory research is its extreme selectivity. Unlike GHRP-2 or GHRP-6, which can stimulate collateral release of cortisol, prolactin, or ACTH, Ipamorelin focuses almost exclusively on GH release.
Research published in Frontiers in Endocrinology highlights Ipamorelin’s ability to induce a robust GH pulse that remains within the physiological ceiling, avoiding the “bleeding effect” or somatotroph exhaustion. This makes it a preferred reagent for longitudinal vitality studies and metabolic research assays.
The Synergistic “GHRH + GHRP” Model
One of the most widely cited dual-ligand protocols in endocrine research involves the combination of CJC-1295 and Ipamorelin. By simultaneously activating the GHRH receptor and the Ghrelin receptor, researchers can observe a “synergistic burst” that is significantly higher than the sum of its parts. GHRH increases the number of somatotrophs secreting GH, while GHRP (Ipamorelin) increases the amount of GH secreted per cell.
Internal Link Navigation
Connect with related research domains for a comprehensive multi-variable somatic assay.
Laboratory Handling &
Verification Standards
Endocrine peptides are highly susceptible to conformational changes if exposed to agitation or suboptimal temperatures. Reconstitution in HPLC-grade bacteriostatic water is standard for multi-use investigative vials. Stability data on CJC-1295 and Ipamorelin suggests that these compounds remain potent for up to 21 days when refrigerated between 2°C and 8°C after first reconstitution.
HPLC & MS Traceability
For research data to be credible, the reagent purity floor must be ≥99%. Vitanx Research utilizes High-Performance Liquid Chromatography (HPLC) to filter out enantiomers and amino acid deletions. Mass Spectrometry (MS) confirms the primary sequence identity, ensuring no off-target signaling occurs during sensitive endocrine assays.
Endocrine Research FAQ
How does CJC-1295 influence IGF-1 levels?
By maintaining a higher basal GH level (in the case of DAC) or increasing pulse amplitude (non-DAC), CJC-1295 triggers the hepatic production of Insulin-like Growth Factor 1 (IGF-1), which is the primary mediator of the somatic effects of growth hormone in research models.
Can Ipamorelin desensitize the pituitary gland?
Research suggests that due to its selective nature and mimicry of the natural ghrelin pulse, Ipamorelin does not cause the rapid desensitization common with GHRP-6 or higher doses of GHRH agonists, allowing for longer-duration research cycles.
What is the molecular mass verification for Ipamorelin?
We verify a molecular mass of exactly 711.8 Da. Any significant variance indicates an impurity or a synthesis error that could compromise hormonal assay reproducibility.
Scientific Sources
- Teichman, S. L., et al. (2006). “Prolonged stimulation of growth hormone (GH) secretion by CJC-1295.” Journal of Clinical Endocrinology & Metabolism.
- Raun, K., et al. (1998). “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology.
- Alba, M., et al. (2006). “Effects of CJC-1295 on GH and IGF-1 secretion.” American Journal of Physiology.
- Vitanx Research Endocrine Catalog Archive. (2024). “Hormonal Axis Stabilization Data.”